How to Get Oral Micronized Progesterone in New York

Why Oral Micronized Progesterone Is Prescribed

Oral micronized progesterone exists for one primary clinical reason: protecting the uterine lining in women who take estrogen. Without a progestogen, unopposed estrogen raises the risk of endometrial hyperplasia and, over time, endometrial cancer. The PEPI trial (N=875) demonstrated that oral micronized progesterone at 200 mg cyclically for 12 days per month prevented endometrial hyperplasia as effectively as medroxyprogesterone acetate (MPA) 10 mg, while producing significantly less adverse effect on HDL cholesterol [1]. That lipid advantage made it the preferred progestogen for many clinicians managing menopausal hormone therapy (MHT).

The Endocrine Society's 2015 clinical practice guideline on the treatment of symptoms of menopause recommends micronized progesterone over synthetic progestins for women who require endometrial protection, citing the PEPI lipid data and observational evidence of lower breast cancer risk [2]. The 2022 North American Menopause Society (NAMS) position statement echoes this preference, noting that "micronized progesterone and some progestogens may be associated with lower risk of breast cancer than other progestins" [3].

New York providers prescribe it in two patterns. Cyclic dosing (200 mg nightly for 12 to 14 days each month) produces a withdrawal bleed. Continuous dosing (100 mg nightly every day) avoids monthly bleeding but may cause more irregular spotting in the first six months.

Telehealth Prescribing in New York

New York fully permits telehealth prescribing for hormone therapy, meaning you do not need an in-person visit to start progesterone. The state codified telehealth parity through amendments to its Public Health Law and Insurance Law, requiring insurers to cover telehealth visits at the same rate as in-person encounters. A synchronous video or audio visit with a New York-licensed prescriber satisfies the prescribing requirements.

Several telehealth platforms now serve New York residents for MHT prescribing. HealthRX connects patients with board-certified providers licensed in New York who can evaluate symptoms, order labs, and prescribe oral micronized progesterone during a single visit. Prescriptions are sent electronically to the patient's pharmacy of choice.

The New York State Education Department Office of the Professions licenses physicians, nurse practitioners, and physician assistants who may prescribe progesterone via telehealth. NPs in New York gained full practice authority in 2023 after completing a 3,600-hour collaborative period, so many NPs can now independently prescribe hormone therapy without a collaborating physician agreement [4].

One practical note: New York requires e-prescribing for nearly all prescriptions under the I-STOP Act. Your provider will transmit the progesterone prescription electronically to the pharmacy. Paper prescriptions are not standard practice.

Lab Requirements Before Starting

No single lab panel is universally mandated by New York law before a progesterone prescription. Clinical guidelines, however, recommend baseline testing to confirm menopausal status and rule out contraindications.

A typical pre-prescribing workup includes FSH and estradiol (to confirm menopausal or perimenopausal status in women under 45), a comprehensive metabolic panel, lipid panel, and TSH. The American College of Obstetricians and Gynecologists (ACOG) recommends excluding pregnancy, undiagnosed vaginal bleeding, and active liver disease before initiating any progestogen [5]. Liver function tests matter because oral micronized progesterone undergoes first-pass hepatic metabolism, and the FDA label lists hepatic impairment as a contraindication [6].

An endometrial thickness measurement via transvaginal ultrasound is not required in all cases, but providers may order one if a patient reports postmenopausal bleeding before starting therapy. The threshold that typically triggers biopsy rather than empiric treatment is endometrial thickness of 4 mm or greater, per ACOG Committee Opinion [7].

Telehealth providers can order labs through national draw networks (Quest, Labcorp, and BioReference all have extensive New York locations). Results are typically available within 48 to 72 hours.

How to Get a Prescription in New York: Step by Step

Getting progesterone in New York involves four steps, whether you use telehealth or an in-person provider.

Step 1: Choose a provider. Options include your OB-GYN, an endocrinologist, a menopause-certified provider (NAMS-certified practitioners are searchable at menopause.org), a primary care physician, or a licensed telehealth platform. MDs, DOs, NPs with full practice authority, and PAs with supervisory agreements can all prescribe.

Step 2: Complete the clinical evaluation. The provider reviews symptoms (hot flashes, night sweats, sleep disruption, mood changes), menstrual history, uterine status (intact uterus versus post-hysterectomy), contraindications (active liver disease, known progesterone hypersensitivity, undiagnosed vaginal bleeding, known or suspected breast cancer), and any prior hormone therapy.

Step 3: Complete labs if indicated. Labs are drawn before or within the first week after the visit, depending on provider protocol. Some telehealth platforms send lab kits directly.

Step 4: Receive the prescription. The provider e-prescribes to a retail pharmacy or a 503A compounding pharmacy. Most patients pick up or receive their first supply within two to five business days.

For women already taking progesterone in another state, transferring a prescription to a New York pharmacy is straightforward. The receiving pharmacist contacts the originating pharmacy to verify and transfer. No new prescription from a New York provider is required for a transfer, though insurance formulary differences may apply.

Pharmacy Options in New York

New York has both retail chain pharmacies dispensing FDA-approved Prometrium (and its generics) and 503A compounding pharmacies that prepare custom progesterone formulations.

Retail pharmacies. CVS, Walgreens, Rite Aid, and independent pharmacies stock generic oral micronized progesterone capsules. These are AB-rated generics manufactured by Teva, Mylan, and others, containing the same USP-grade micronized progesterone in a peanut-oil base. The FDA Orange Book confirms therapeutic equivalence [8]. A 30-day supply of generic progesterone 100 mg typically costs $15 to $40 without insurance. Brand-name Prometrium runs higher, often $90 to $200 for 30 capsules without a coupon.

503A compounding pharmacies. New York's Board of Pharmacy licenses and inspects 503A compounding pharmacies under state law (New York Education Law Section 6830). These pharmacies can compound progesterone in alternative delivery forms (troches, sublingual tablets, topical creams, suppositories) when a prescriber determines a patient-specific clinical need. They cannot ship across state lines without 503B outsourcing facility registration. Patients with peanut allergies represent a common clinical reason for compounding, since FDA-approved capsules use peanut oil as a suspension medium. The FDA's Prometrium label carries a peanut allergy warning [6].

Compounded progesterone is not covered by most insurance plans. Out-of-pocket costs range from $30 to $80 per month depending on the formulation and pharmacy.

Insurance and Medicaid Coverage in New York

New York Medicaid covers oral micronized progesterone for endometrial protection in women on estrogen therapy. Prior authorization is required. The PA process typically involves the prescriber submitting documentation that the patient has an intact uterus, is receiving concomitant estrogen, and has no contraindications.

Commercial insurers in New York generally place generic oral micronized progesterone on Tier 1 or Tier 2 of their formularies. Brand-name Prometrium often sits on Tier 3 or requires step therapy through the generic first. Under the New York State Insurance Law's telehealth parity provisions, the visit itself is covered at in-network rates regardless of modality.

Prior authorization documentation typically includes:

• Diagnosis code (most commonly N95.1 for menopausal and female climacteric states, or Z79.890 for long-term HRT)
• Confirmation of intact uterus
• Name and dose of concurrent estrogen therapy
• Notation of any contraindication to synthetic progestins (this strengthens the case for micronized progesterone specifically)
• Lab results showing menopausal FSH/estradiol if the patient is under 45

PA turnaround in New York averages two to five business days. Emergency or expedited reviews can be completed within 24 hours when clinically justified.

The New York State Department of Financial Services oversees insurance compliance, and patients can file complaints if a PA is wrongly denied. Federal protections under the ACA also require coverage of preventive services, though progesterone for endometrial protection is classified as treatment rather than prevention by most payers.

Dosing and Clinical Monitoring

The FDA-approved dosing of Prometrium for endometrial protection is 200 mg orally at bedtime for 12 consecutive days per 28-day cycle when used with conjugated estrogens 0.625 mg [6]. Bedtime administration is not arbitrary. Progesterone causes drowsiness through its metabolite allopregnanolone, a GABA-A receptor agonist, and evening dosing turns this side effect into a clinical benefit for women with menopausal insomnia.

Continuous combined dosing uses 100 mg nightly every day. A 2012 Cochrane review of progestogens for endometrial protection found continuous regimens produced lower rates of hyperplasia than cyclic regimens but more unscheduled bleeding in the first year [9].

Monitoring after initiation follows standard MHT practice. The Endocrine Society recommends reassessing symptoms, bleeding patterns, and side effects at three months, then annually [2]. Annual mammography remains standard. Endometrial biopsy is indicated only if unexpected bleeding occurs after the first six months of therapy. Routine progesterone blood levels are not clinically useful for oral dosing because of rapid hepatic metabolism and wide inter-individual variation in bioavailability.

Patients should report any of the following to their provider promptly: persistent unscheduled bleeding beyond six months, breast tenderness that worsens over time, severe headaches, or jaundice.

Who Can Prescribe in New York: MD vs. NP vs. PA

Three categories of clinicians hold prescriptive authority for progesterone in New York.

Physicians (MD and DO). No restrictions on prescribing hormone therapy. Board certification in endocrinology, obstetrics-gynecology, or internal medicine is common but not legally required.

Nurse Practitioners. Since January 2023, NPs who have completed 3 to 600 hours of supervised practice have full practice authority in New York and can prescribe independently [4]. NPs still within their collaborative period require a written practice agreement with a physician. Both groups can prescribe progesterone.

Physician Assistants. PAs prescribe under a collaborative agreement with a supervising physician. The agreement must be filed with the New York State Education Department. PAs can prescribe Schedule VI drugs (which includes progesterone) without additional DEA registration since progesterone is not a controlled substance.

Pharmacists cannot independently prescribe progesterone in New York. They can, however, dispense emergency refills for maintenance medications under specific circumstances outlined in the state's pharmacy practice act.

Timeline: From First Visit to First Dose

Speed matters when a patient is symptomatic. Here is a realistic timeline for a New York resident starting oral micronized progesterone through telehealth.

Day 1: Schedule and complete a telehealth visit. Many platforms offer same-day or next-day appointments. Lab orders are placed during the visit.

Days 2 to 4: Complete lab draw at a local Quest, Labcorp, or BioReference location. Results return in one to three business days.

Days 3 to 5: Provider reviews labs and, if appropriate, e-prescribes progesterone.

Days 4 to 7: Pharmacy fills the prescription. Retail pharmacies typically fill within 24 hours. Compounding pharmacies may take two to four business days.

Total elapsed time from initial appointment to first dose: four to seven days for most patients using generic progesterone at a retail pharmacy. Compounded formulations may add two to three days. If prior authorization is required, add two to five business days. The NAMS 2022 position statement emphasizes that treatment delays can worsen vasomotor symptoms and sleep disruption, supporting prompt initiation when clinically appropriate [3].

Dr. Stephanie Faubion, NAMS Medical Director, has stated: "Hormone therapy remains the most effective treatment for vasomotor symptoms and should not be withheld from appropriate candidates based on outdated safety concerns" [3].